Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 55

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 55
---
 development and commercial manufacturing activities;

    ●
    the extent to which we acquire or in-license other drug candidate and technologies;

    ●
    the cost, timing and outcome of regulatory review of our drug candidate;

    ●
    the cost and timing of establishing sales and marketing capabilities, if our drug candidate receives marketing approval;

    ●
    the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

    ●
    our ability to establish and maintain collaborations on favorable terms, if at all;

    ●
    our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our drug candidate;

    ●
    the costs associated with being a public company; and

    ●
    the cost associated with commercializing our drug candidate, if it receives marketing approval.

26

If we raise additional funds
by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon
us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends,
repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt
financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise
additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials.
We may also be required to sell or license to other parties rights to develop or commercialize our drug candidate that we would prefer
to retain.

See “Risk
Factors” included herein and in our 2024 Annual Report on Form 10-K for fiscal 2024 filed with the Securities and Exchange
Commission (the “SEC”) on March 28, 2025 for additional discussion of risks associated with our capital
requirements.

Cash Flows for the Three Months Ended March
31, 2025 and 2024

The following table shows
a summary of our cash flows for the three months ended March 31, 2025 and 2024.

    For the Three Months Ended March 31, 

    2025  
    2024 
  
    Net cash flows from operating activities 
    $(1,063,041) 
    $(65,165)
  
    Net cash flows from